- Home
- SEED vs SABS Comparison
SEED vs SABS Comparison
Compare SEED & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEED
- SABS
- Stock Information
- Founded
- SEED 1997
- SABS 2014
- Country
- SEED China
- SABS United States
- Employees
- SEED N/A
- SABS N/A
- Industry
- SEED Farming/Seeds/Milling
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- SEED Consumer Staples
- SABS Health Care
- Exchange
- SEED Nasdaq
- SABS Nasdaq
- Market Cap
- SEED 16.1M
- SABS 19.0M
- IPO Year
- SEED N/A
- SABS N/A
- Fundamental
- Price
- SEED $2.02
- SABS $1.82
- Analyst Decision
- SEED
- SABS Strong Buy
- Analyst Count
- SEED 0
- SABS 5
- Target Price
- SEED N/A
- SABS $12.40
- AVG Volume (30 Days)
- SEED 128.0K
- SABS 246.2K
- Earning Date
- SEED 02-10-2025
- SABS 03-28-2025
- Dividend Yield
- SEED N/A
- SABS N/A
- EPS Growth
- SEED N/A
- SABS N/A
- EPS
- SEED 0.46
- SABS N/A
- Revenue
- SEED $16,163,803.00
- SABS $1,512,723.00
- Revenue This Year
- SEED N/A
- SABS N/A
- Revenue Next Year
- SEED N/A
- SABS N/A
- P/E Ratio
- SEED $4.43
- SABS N/A
- Revenue Growth
- SEED 21.51
- SABS N/A
- 52 Week Low
- SEED $1.64
- SABS $1.60
- 52 Week High
- SEED $6.38
- SABS $6.30
- Technical
- Relative Strength Index (RSI)
- SEED 42.55
- SABS 36.28
- Support Level
- SEED $2.08
- SABS $2.00
- Resistance Level
- SEED $2.21
- SABS $2.15
- Average True Range (ATR)
- SEED 0.21
- SABS 0.20
- MACD
- SEED -0.03
- SABS 0.03
- Stochastic Oscillator
- SEED 12.82
- SABS 30.99
About SEED Origin Agritech Limited
Origin Agritech Ltd is a Chinese agricultural technology company. In crop seed biotechnologies, the company's phytase corn was the first transgenic corn to receive the Bio-Safety Certificate from China's Ministry of Agriculture. Origin has established a robust biotechnology seed pipeline including products with glyphosate tolerance and pest resistance (Bt) traits.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.